Dengue vaccine development by the year 2020: challenges and prospects.
Curr Opin Virol
; 43: 71-78, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-987407
ABSTRACT
The first licensed dengue vaccine led to considerable controversy, and to date, no dengue vaccine is in widespread use. All three leading dengue vaccine candidates are live attenuated vaccines, with the main difference between them being the type of backbone and the extent of chimerization. While CYD-TDV (the first licensed dengue vaccine) does not include non-structural proteins of dengue, TAK-003 contains the dengue virus serotype 2 backbone, and the Butantan/Merck vaccine contains three full-genomes of the four dengue virus serotypes. While dengue-primed individuals can already benefit from vaccination against all four serotypes with the first licensed dengue vaccine CYD-TDV, the need for dengue-naive population has not yet been met. To improve tetravalent protection, sequential vaccination should be considered in addition to a heterologous prime-boost approach.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dengue
/
Dengue Virus
/
Dengue Vaccines
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Curr Opin Virol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS